Myoscience’s FDA-cleared platform technology, the iovera° system, uses cryoneurolysis to freeze nerves in the knee to deliver fast and immediate opioid-free pain relief with results that are sustained for up to 90 days.1 During the simple outpatient procedure, iovera° safely and effectively allows patients with knee pain to leave their physician’s office experiencing less pain than they had when they walked in.
“While knee replacement surgery is an effective option for relieving pain and restoring function for patients, concern has shifted to addressing how outcomes are negatively affected by the prolonged use of opioids,” said Dr. Mihalko. “Cryoneurolysis with the iovera° system has made a measurable impact on pain relief, reduced patients’ use of opioids after surgery and improved overall knee function. I am seeing my patients recover more quickly, with less pain. We are confident the progress demonstrated by the positive preliminary data presented today is a strong indication for the final results of this clinical trial.”
Presentation time and location:
Cryoanalgesia: A Path to an Opioid-Free TKA, Pre-op Through Rehab
Presented by lead author William Mihalko, M.D., Ph.D.
Wednesday, March 13, 2:15 p.m. PT
Innovation Theater, Booth 3032, Hall B
About the Campbell Clinic Orthopaedics Study
Patients scheduled to undergo a primary TKA (n = 125) were randomized 1:1 to a control group or a cryoneurolysis treatment group. Both groups followed the same pre-operative, intra-operative, and post-operative pain management protocols, except that the treatment group had the iovera° therapy administered to their superficial genicular nerves three to seven days before surgery. All patients were prescribed 40 opioid pills at discharge, and pills were counted at 72 hours and at two, six, and 12 weeks postoperatively.
The iovera° system met preliminary primary and secondary endpoints, including:
- Daily morphine equivalent (DME), (primary endpoint, a measure taking of prescribed opioids based on pill count). DME was significantly lower at 72 hours (12.1 mg vs. 17.8 mg, p=0.014), six weeks (4.5 mg vs. 6.3 mg, p=0.025) and 12 weeks (2.3 mg vs 3.5 mg p=0.008) with an overall 35 percent reduction in the DMEs across the 12-week postoperative period in the iovera° treatment group.
- Opioid use. Patients who had iovera° therapy were far less likely to take opioids six weeks after surgery. The number of patients taking opioids six weeks after TKA in the control group was three times the number of patients taking opioids in the cryoneurolysis treatment group.
- Pain score. Patients in the iovera° treatment group demonstrated a significant reduction in pain scores from the baseline at 72 hours (0.59 vs. -0.60, p=0.021) and at 12 weeks (4.6 vs. 3.5, p=0.014).
“These data mark important progress in establishing iovera° therapy as a clinically-validated alternative to opioids for patients recovering from total knee replacement,” said Timothy I. Still, president and CEO of Myoscience. “This trial represents our commitment to developing innovative technologies that offer a safe and reliable option for people suffering from chronic knee pain. We are grateful to Campbell Clinic Orthopaedics for leading this effort and making this trial possible.”
1 Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10.